Can SARS-CoV-2 change individual radiation sensitivity of the patients recovered from COVID-19? (experimental and theoretical background)
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-3.16554Keywords:
cancer patients, coronavirus SARS-CoV-2, individual radiosensitivity, ionizing radiation, professionalsAbstract
Summary. R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Science of Ukraine has been studying the mechanisms and specificities of individual radiation sensitivity (IRS) formation in professionals who work in the field of ionizing radiation, cancer patients and representatives of other population groups. Our data based on the use of G2-test in in vitro irradiated blood lymphocytes in late G2-period of cell cycle indicated an increased carcinogenic risk in professionals with high IRS. We suggest that the COVID-19 pandemic could make significant adjustments in the formation of IRS in professionals who have survived the disease and continue to work with ionizing radiation (IR). Increased systemic inflammatory activity, which persists for a long time in COVID-19 patients, in combination with low-dose range irradiation (professionals who continue to work with IR) and with local irradiation in the high-dose range (radiation therapy for cancer patients) may affect IRS. Repeated determination of IRS in professionals who have had COVID-19 infection, using chromosomal G2-radiation sensitivity assay will answer the question: can SARS-CoV-2 coronavirus affect the IRS? The proposed hypothesis of the radiosensitivity evolution needs further experimental validation using a set of radiobiological indices to clarify the mechanism of IRS formation following COVID-19 infection. The detected changes (increase) of human IRS after COVID-19 must be taken into account for personalized planning of radiotherapy of COVID-19 cancer patients.
References
Bushmanov AYu, Galstyan IA, Soloviev VYu, Konchalovsky MV. Lessons for health service: the Chernobyl accident and the COVID-19 pandemic. Med Radiol Radiat Safety 2020; 65: 79–84 (in Russian).
Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). The provisional guidelines. Version 28.04.2020. https://docviewer.yandex.ru/view/131721953/jama.2020.3786 1.06.2020.
Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020; 323: 1843–4. doi: https://doi.org/10.1001/jama.2020.3786 1.06.2020.
Domina EA, Mykhailenko VM. The argumentation of the prevention of radiogenic cancer in professionals that work in the fields of ionizing radiation using biological methods. Oncologiya 2018; 20: 177–84 (in Ukrainian).
Domina E, Philchenkov A, Dubrovska A. Individual response to ionizing radiation and personalized radiotherapy. Crit Rev Oncog USA 2018; 23: 69–92. doi: 10.1615/CritRevOncog.2018026308.
Domina EA, Chekhun VF. Experimental validation of prevention of the development of stochastic effects of low doses of ionizing radiation based on the analysis of human lymphocytes’ chromosome aberrations. Exp Oncol 2013; 35: 65–8. PMID: 23528319.
Domina EA, Gontar JV, Illyuchok LA, Grynchenko OO. Evaluation of the individual radiosensitivity of a person on the basis of the differentiated coloring of chromosomes in peripheral blood lymphocytes. Rep Nat Acad Sci Ukraine 2019; 7: 81–8 (in Ukrainian).
Kumar M, Narla A, Nonami A, et al. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q-syndrome. Blood 2011; 118: 4666–73. https://doi.org/10.1182/blood2010-12-324715.
Gabrea A, Bergsagel P, Kuehl W. Distinguishing primary and secondary translocations in multiple myeloma: a review. DNA Repair (Amst) 2006; 5: 1225–33. doi: https://doi.org/10.1016/j.dnarep.2006.05.012.
Brunelli M, Fiorentino M, Gobbo S, et al. Many facets of chromosome 3p cytogenetic findings in clear cell renal carcinoma: the need for agreement in assessment FISH analysis to avoid diagnostic errors: a review. Histol Histopathol 2011: 26: 1207–13. doi: https://doi.org/10.14670/HH-26.1207.
Doheny K. Low-dose radiation therapy may help COVID-19 patients. WebMD Health News. https://www.webmd.com/lung/news/20200618/low-dose-radiation-therapy-may-help-covid-patients
Cascella M, Rajnik M, Aleem A, et al. Features, Evaluation, and Treatment of Coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. PMID: 32150360.
Komisarenko SV. World Coronavirus Crisis. Kyiv: LAM & K, 2020. 120 p. (in Ukrainian).
Komisarenko SV. Scientist’s pursuit for coronavirus SARS-COV-2, which causes COVID-19: scientific strategies against pandemic. Visnyk Nat Acad Sci Ukraine 2020; (8): 29–71 (in Ukrainian). doi: https://doi.org/doi.org/10.15407/ visn2020.08.029
Yasqur BS. Three stages to COVID-19 brain damage, new review suggest. Medcape/ June 29, 2020. https://www. medcape.com/viewarticle/993131
Joiner MC, van der Kogel AJ, eds. Basic Clinical Radiobiology. Boca Raton, FL: CRC Press, 2018: 229 p.
Choi WH, Cho J. Evolving clinical cancer radiotherapy: Concerns regarding normal tissue protection and quality assurance. J Korean Med Sci 2016; 31: 75–8. doi: https://doi.org/10.3346/jkms.2016.31.S1.S75.
Denham JW, Hauer-Jensen M. The radiotherapeutic injury — a complex “wound”. Radiother Oncol 2002; 63: 129–45. doi: https://doi.org/10.1016/s0167-8140(02)00060-9.
Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000; 88: 398–406. doi: 10.1002/(sici) 1097-0142(20000115)88:2<398::aid-cncr22>3.0.co;2-v.
Denham JW, Hauer-Jensen M, Peters LS. Is it time for a new formalism to categorize normal tissue radiation injury? Int J Radiat Oncol Biol Phys 2001; 50: 1105–6. doi: https://doi.org/10.1016/s0360-3016(01)01556-5.
Akleev AV. Radiobiological patterns of the reaction of normal tissues during radiation therapy of tumours. Radiobiol Radioecol 2014; 54: 241–53 (in Russian). doi: https://doi.org/10.7868/S0869803114030035.
Domina EA, Ryabchenko NM. Determination of individual radiosensitivity of healthy donors on the basis of cytogenetic investigations. Curr Probl Rad Res. Proc 35th Annual Meeting of the ERRS. Kyiv: Inst of Cell Biol & Genet Engineering; 2007: 162–8.
Ryabchenko NM, Glavin OA, Shtefura VV, Anikusko NF. Chromosomal radiosensitivity in Ukrainian breast cancer patients and healthy individuals. Exp Oncol 2012; 34: 1–4. PMID: 23013765.
Distel LVR, Neubauer S, Keller U, et al. Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients. Radiother Oncol 2006; 81: 257–63. doi: https://doi.org/10.1016/j.radonc.2006.10.012.
Ryabchenko NN, Domina EA. Radiation-induced instability of human genome. Probl Radiat Med Radiobiol 2014; 19: 48–58. PMID: 25536547.
Philchenkov OO, Zavelevich MP, Domina EA, Glavin OA. Apoptosis of peripheral blood lymphocytes in patients with prostate cancer induced by in vitro irradiation. Onkologiya 2019; 21: 282–9 (in Ukrainian). doi: https://doi.org/10.32471/oncology.2663-7928.t-21-4-2019-g.8142.
Vasin MV, Solov’ev VYu, Mal’tsev VN, et al. Primary radiation stress, inflammatory reaction and the mechanism of early postradiation reparative processes in irradiated tissues. Med Radiol Radiat Safety 2018; 63: 71–81 (in Russian). doi: 10.12737/article_5c0eb50d2316f4.12478307.
Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest 2009; 39: 618–25. doi: https://doi.org/10.1111/j:1365-2362.2009.02153.x.
Kopytsya NN, Rodionova YuV, Tytarenko NV, et al. Features of the cardiovascular system lesion in patients with COVID-19. Science Rise: Med Sci 2020; 3: 4–12 (in Russian).
Domina E. Expediency on using radiomitigators in radiation therapy of cancer patients. J Sci, Lyon-France 2020; (10): 7–11 (in Russian). http://www.joslyon.com/wp-content/uploads/2020/08/Lyon_10_1.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
